Joint Venture4 Dec 2025, 01:26 pm
Lupin and Valorum Enter Exclusive Licensing Agreement for Biosimilar Armlupeg in the U.S.
AI Summary
Global pharma major Lupin Limited has entered into an Exclusive Licensing Agreement with Valorum Biologics for its biosimilar Armlupeg™ (pegfilgrastim-unne). Under the agreement, Valorum will commercialize and distribute Armlupeg™ in the United States, while Lupin will handle manufacturing and supply. The partnership aims to expand access to affordable treatment options for patients undergoing chemotherapy and strengthen Lupin's presence in the U.S. biosimilars market.
Key Highlights
- Lupin and Valorum enter an Exclusive Licensing Agreement for biosimilar Armlupeg™ (pegfilgrastim-unne) in the U.S.
- Valorum to advance commercialization and distribution, Lupin to manufacture and supply
- Partnership aims to expand access to affordable treatment options for chemotherapy patients
- Lupin to strengthen its presence in the U.S. biosimilars market
- Valorum expects to capture significant market share through commercial expertise